OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial - Ars Technica
The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.
Search Group
Share To
Comments
About Screade
Screade® Inc. version 2f0093a, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments